AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14601715 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation with low tidal volumes
Number of subjects: 0
Study 10690696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation for malnourished residents (score <17)
Number of subjects: 88
Study 10690696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation for residents at risk of malnutrition (score 17-23.5)
Number of subjects: 88
Study 10690696 — intervention group
Group type: COMPARATOR
Intervention: No oral supplementation for residents with score 24
Number of subjects: 88
Study 9339691 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg tid
Number of subjects: 202
Study 9339691 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg tid
Number of subjects: 202
Study 9339691 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone groups
Number of subjects: 202
Study 9339691 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202
Study 8274414 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy for 1 month (n = 12)
Number of subjects: 19
Study 8274414 — intervention group
Group type: COMPARATOR
Intervention: Long-term oxygen therapy for 24 hours (n = 7)
Number of subjects: 19
Study 3011048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimazosin (200 mg)
Number of subjects: 12
Study 3011048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trimazosin (100 mg)
Number of subjects: 12
Study 3011048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3011048 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments (oral and intravenous trimazosin)
Number of subjects: 12
Study 30084472 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (CP)
Number of subjects: 40
Study 30084472 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (HP)
Number of subjects: 40
Study 27874935 — intervention group
Group type: EXPERIMENTAL
Intervention: BLIS K12 (Bactoblis) daily for 6 months
Number of subjects: 222
Study 27874935 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 222
Study 27874935 — intervention group
Group type: EXPERIMENTAL
Intervention: BLIS K12 (Bactoblis) during 3 months follow-up
Number of subjects: 222
Study 27874935 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated) during 3 months follow-up
Number of subjects: 222
Study 26145468 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt treatment for 17 days along with dental sanitation and treatment of gingivitis
Number of subjects: 49
Study 26145468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 23800571 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus eluting stents
Number of subjects: 2265
Study 23800571 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus eluting stents
Number of subjects: 2265
Study 21124768 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E)
Number of subjects: 894
Study 21124768 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 894
Study 19020153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal morphine 7.5 mg
Number of subjects: 225
Study 19020153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal morphine 15 mg
Number of subjects: 225
Study 19020153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 7.5 mg
Number of subjects: 225
Study 19020153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine 60 mg
Number of subjects: 225
Study 19020153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 16877482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin A to tacrolimus conversion (group A, target tacrolimus trough level 6-8 ng/ml)
Number of subjects: 34
Study 16877482 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin A minimization (group B, target CsA trough level 80-100 ng/ml)
Number of subjects: 34
Study 16877482 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft survival in group A
Number of subjects: 34
Study 16877482 — intervention group
Group type: COMPARATOR
Intervention: Graft survival in group B
Number of subjects: 34
Study 16877482 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rejection in group A
Number of subjects: 34
Study 16877482 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose, lipids, and blood pressure
Number of subjects: 34
Study 12460290 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifuged fat
Number of subjects: 14
Study 12460290 — intervention group
Group type: COMPARATOR
Intervention: Noncentrifuged fat
Number of subjects: 14
Study 10385545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based treatment after cytoreductive surgery
Number of subjects: 456
Study 8630559 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nebulized natural-derived bovine surfactant (Alveofact)
Number of subjects: 12
Study 8630559 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl nebulization
Number of subjects: 12
Study 1709311 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution with hydroxyethyl starch (10%, 200/0.5)
Number of subjects: 70
Study 1709311 — intervention group
Group type: COMPARATOR
Intervention: Control (no hemodilution)
Number of subjects: 70
Study 1709311 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution group
Number of subjects: 70
Study 7028643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade purity ampicillin
Number of subjects: 0
Study 7028643 — intervention group
Group type: COMPARATOR
Intervention: Slightly contaminated ampicillin
Number of subjects: 0
Study 7028643 — intervention group
Group type: COMPARATOR
Intervention: Combined analysis of pure vs contaminated ampicillin
Number of subjects: 0
Study 31981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative feedback
Number of subjects: 0
Study 31981584 — intervention group
Group type: COMPARATOR
Intervention: Quantitative feedback
Number of subjects: 0
Study 30108162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 188
Study 30108162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 28978542 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs (18 g protein, 17 g fat)
Number of subjects: 10
Study 28978542 — intervention group
Group type: COMPARATOR
Intervention: Egg whites (18 g protein, 0 g fat)
Number of subjects: 10
Study 28978542 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs
Number of subjects: 10
Study 28978542 — intervention group
Group type: COMPARATOR
Intervention: Egg whites
Number of subjects: 10
Study 28978542 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs and egg whites
Number of subjects: 10
Study 27144780 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice, Control, and Change curriculum
Number of subjects: 1136
Study 24258099 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 22
Study 24258099 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 22
Study 24258099 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 22648465 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-set resistance training (RT) 3 times/week, 9 exercises, resistance of 3-6 repetition maximum (RM)
Number of subjects: 63
Study 22648465 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-set resistance training (RT)
Number of subjects: 63
Study 22648465 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 63
Study 19512875 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-ProSeal (PLMA)
Number of subjects: 48
Study 19512875 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (control)
Number of subjects: 48
Study 17445178 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory KIR-HLA genotype combinations
Number of subjects: 0
Study 17445178 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating KIR genotypes
Number of subjects: 0
Study 17445178 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite inhibitory and activating KIR-HLA genotype models
Number of subjects: 0
Study 10837378 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles and occlusion (n = 69)
Number of subjects: 86
Study 10837378 — intervention group
Group type: COMPARATOR
Intervention: Spectacles only (n = 17)
Number of subjects: 86
Study 10837378 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion (up to >1000 hours, analyzed in blocks of 200 hours)
Number of subjects: 86
Study 10837378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 86
Study 9221313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue and neostigmine tests
Number of subjects: 11
Study 1362592 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 117
Study 1362592 — intervention group
Group type: COMPARATOR
Intervention: Antiparkinsonian drugs withdrawal
Number of subjects: 117
Study 3890428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) in multiple modality therapy
Number of subjects: 71
Study 3890428 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment without HBO
Number of subjects: 71
Study 30737609 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI testing acceptance
Number of subjects: 341
Study 30737609 — intervention group
Group type: EXPERIMENTAL
Intervention: Declined testing
Number of subjects: 341
Study 30737609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lost to follow-up (LTFU)
Number of subjects: 341
Study 30737609 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of LTFU
Number of subjects: 341
Study 29100251 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day memantine
Number of subjects: 32
Study 29100251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27770801 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance chiropractic therapy (BCT)
Number of subjects: 0
Study 27770801 — intervention group
Group type: COMPARATOR
Intervention: Traction therapy (TT)
Number of subjects: 0
Study 27770801 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT
Number of subjects: 0
Study 27770801 — intervention group
Group type: COMPARATOR
Intervention: TT
Number of subjects: 0
Study 24911580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 47
Study 24911580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 22424834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (verteporfin 6 mg/m² PDT and ranibizumab 0.5 mg)
Number of subjects: 255
Study 22424834 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (sham infusion [5% dextrose] PDT and ranibizumab 0.5 mg)
Number of subjects: 255
Study 22424834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 255
Study 22424834 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 255
Study 19996947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (300 mg loading dose followed by 15 mg/kg/24h for 2 days)
Number of subjects: 120
Study 19996947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18292850 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSs alone
Number of subjects: 1003
Study 18292850 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS plus LABA
Number of subjects: 1003
Study 18292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 1003
Study 18292850 — intervention group
Group type: COMPARATOR
Intervention: Controlled asthma
Number of subjects: 1003
Study 18292850 — intervention group
Group type: EXPERIMENTAL
Intervention: General education level
Number of subjects: 1003
Study 18292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication compliance
Number of subjects: 1003
Study 18292850 — intervention group
Group type: COMPARATOR
Intervention: Family physicians' perception
Number of subjects: 1003
Study 18292850 — intervention group
Group type: COMPARATOR
Intervention: FPs' estimate of OP symptoms
Number of subjects: 1003
Study 18292850 — intervention group
Group type: COMPARATOR
Intervention: FPs' perception of treatment compliance
Number of subjects: 1003
Study 15996628 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg, levofloxacin 500 mg and azithromycin 500 mg once-daily (ELAz)
Number of subjects: 164
Study 15996628 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20mg, clarithromycin 500 mg and amoxycillin 1g twice-daily (ECA)
Number of subjects: 164
Study 14514942 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum KL-6 levels measured by a sandwich enzyme linked immunosorbent assay
Number of subjects: 30
Study 14514942 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum KL-6 levels
Number of subjects: 30
Study 10561096 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy (PcT)
Number of subjects: 70
Study 10561096 — intervention group
Group type: COMPARATOR
Intervention: Surgical tracheostomy (SgT)
Number of subjects: 70
Study 9051521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic IOLs
Number of subjects: 55
Study 9051521 — intervention group
Group type: COMPARATOR
Intervention: Silicone IOLs
Number of subjects: 55
Study 9051521 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA IOLs
Number of subjects: 55
Study 1984762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 315
Study 1984762 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 315
Study 30394552 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion with one unit of RBCs at a hemoglobin level of 9.0 g/dL
Number of subjects: 58
Study 30394552 — intervention group
Group type: COMPARATOR
Intervention: Transfusion with one unit of RBCs at a hemoglobin level of 7.0 g/dL
Number of subjects: 58
Study 30394552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low platelet function (assessed by MEA)
Number of subjects: 58
Study 26577998 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 115
Study 26577998 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 115
Study 26577998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Levofloxacin + Terazosin)
Number of subjects: 115
Study 26577998 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Levofloxacin, Terazosin, Combination)
Number of subjects: 115
Study 25247319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological examination using a capsule sponge device
Number of subjects: 344
Study 25247319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological examination combined with p53 staining
Number of subjects: 344
Study 25247319 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient acceptability assessment using a visual analogue scale
Number of subjects: 344
Study 22539051 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling with 90-min post-infusion cooling time (PICT)
Number of subjects: 53
Study 22539051 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling with 90-min PICT
Number of subjects: 53
Study 22539051 — intervention group
Group type: COMPARATOR
Intervention: Scalp cooling with 45-min PICT
Number of subjects: 53
Study 22539051 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling
Number of subjects: 53
Study 20862939 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and snake moxibustion (group A)
Number of subjects: 120
Study 20862939 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (group B)
Number of subjects: 120
Study 20862939 — intervention group
Group type: COMPARATOR
Intervention: Snake moxibustion (group C)
Number of subjects: 120
Study 18666496 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0
Number of subjects: 18
Study 18666496 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 18
Study 18666496 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink
Number of subjects: 18
Study 18666496 — intervention group
Group type: COMPARATOR
Intervention: Die spacer group
Number of subjects: 18
Study 18666496 — intervention group
Group type: COMPARATOR
Intervention: Dentin margins
Number of subjects: 18
Study 16786786 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods for prevention and treatment of postoperative nausea and vomiting (PONV)
Number of subjects: 0
Study 12730560 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA; Actilyse) administered up to 6 hours after stroke
Number of subjects: 1000
Study 12730560 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA; Actilyse)
Number of subjects: 1000
Study 10632905 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical axillary block with 2 mg.kg-1 of 0.25% bupivacaine
Number of subjects: 55
Study 10632905 — intervention group
Group type: COMPARATOR
Intervention: Postsurgical axillary block with 2 mg.kg-1 of 0.25% bupivacaine
Number of subjects: 55
Study 8701508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract GB‐8 at a dose of 120 mg o.d.
Number of subjects: 18
Study 8701508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1953853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin after four hours of observation
Number of subjects: 47
Study 1953853 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal 3 mg PGE2 gel followed by intravenous oxytocin four hours later
Number of subjects: 47
Study 6602328 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 4.0 g/day
Number of subjects: 36
Study 6602328 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1,000 mg/day
Number of subjects: 36
Study 6602328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29596218 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT supplementation (n = 8)
Number of subjects: 12
Study 29596218 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (n = 4)
Number of subjects: 12
Study 28774521 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart phone television display (SPTD)
Number of subjects: 38
Study 26590513 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (PFI)
Number of subjects: 70
Study 25079399 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal Plaque Index (MPI)
Number of subjects: 131
Study 25079399 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal hygiene treatment (study 1)
Number of subjects: 131
Study 25079399 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing (study 2)
Number of subjects: 131
Study 25079399 — intervention group
Group type: COMPARATOR
Intervention: Turesky modification of the Quigley and Hein Index (TQHI)
Number of subjects: 131
Study 23866471 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg) given orally at 10:00 pm the night before operation and at 7:00 am on the day of surgery
Number of subjects: 170
Study 23866471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Trimetazidine)
Number of subjects: 170
Study 18599252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recursive partitioning (RP) methodology applied to drug treatment retention analysis
Number of subjects: 315
Study 17697500 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists (GnRHa) plus gonadotrophin therapy with corticosteroids (dexamethasone)
Number of subjects: 58
Study 17697500 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonists (GnRHa) plus gonadotrophin therapy with placebo
Number of subjects: 58
Study 16138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (0.3 mg)
Number of subjects: 1186
Study 16138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (1.0 mg)
Number of subjects: 1186
Study 16138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (3.0 mg)
Number of subjects: 1186
Study 16138974 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival sham injection (Control)
Number of subjects: 1186
Study 12012289 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient hypothyroxinemia of prematurity (THOP) defined by T4 <5.3 microg/dL without elevated TSH
Number of subjects: 54
Study 12012289 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with THOP
Number of subjects: 54
Study 9449910 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tazarotene gel administered once or twice daily
Number of subjects: 153
Study 9449910 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene gel administered once or twice daily
Number of subjects: 153
Study 9449910 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 153
Study 2699148 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum insertion of intrauterine contraceptive devices (IUDs) within 10 minutes after placental delivery
Number of subjects: 0
Study 2699148 — intervention group
Group type: COMPARATOR
Intervention: Postpartum insertion of IUDs
Number of subjects: 0
Study 406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 5 microng/kg
Number of subjects: 42
Study 406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 8 microng/kg
Number of subjects: 42
Study 406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 10 microng/kg
Number of subjects: 42
Study 406632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 5 microng/kg (second experiment)
Number of subjects: 42
Study 406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 10 microng/kg (second experiment)
Number of subjects: 42
Study 406632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (second experiment)
Number of subjects: 42
Study 31038476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification treatment (diet, rehabilitation, education, behavioral therapy) for 12 weeks
Number of subjects: 200
Study 31038476 — intervention group
Group type: COMPARATOR
Intervention: Lean individuals (controls)
Number of subjects: 200